NASDAQ:NVAX

16.52
0.32 (1.87%) 1d
0
SELL
Historically not a successful vaccine developer. Shares were $258 last November but fallen to $42. This can fall further. He's never liked it.
Pharma & Healthcare

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock the latest opinion & get signals
DON'T BUY
The variability around earnings makes it interesting to trade, but he would not recommend investing in it. Very volatile. No insight for approval. Prefers using XPI ETF to trade the sector. NVAX is not a name he owns.
Pharma & Healthcare
DON'T BUY
The share price and PE have plunged in the past year. Though cheaper to buy, he passes, because they haven't gotten FDA approval for their Covid vaccine.
Pharma & Healthcare
DON'T BUY
Issued a Covid vaccines that the EU and WHO approved recently. He likes Pfizer in this group; you don't need another one. NVAX is up 6% in the past week.
Pharma & Healthcare
WEAK BUY
Eventually, a full, broad-spectrum vaccine will be in place to cover Covid. Will MRNA technology also develop drugs to tackle TV and HIV and other diseases. Novartis offers more a strong balance sheet and a just-announced $20 billion inflow, based on tuck-in acquisition. NVAX is fine, but there are better companies.
Pharma & Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jul 21/21, Down 16.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with NVAX has triggered its stop at $175. To remain disciplined, we recommend covering the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment gain of 6%.
Pharma & Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jul 22/21, Up 29.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with NVAX has achieved its target at $272. To be disciplined, we recommend covering half the position at this time and trailing up the stop (from $160) to $175.
Pharma & Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly NVAX is applying for Emergency Use Authorization for its COVID-19 vaccine as experts believe annual boosters may be required as with the annual flu shots. It has achieved over 89% efficacy and does not require deep freeze storage -- a huge advantage. It has agreements already in place for 180 million doses in the UK, Canada, and Australia when approved. We would buy this with a stop loss at $160, looking to achieve $272 -- upside potential over 27%. Yield 0%. (Analysts’ price target is $271.75)
Pharma & Healthcare
DON'T BUY
Recently announced an effective Covid vaccine In 2019, they had less than $50 million in revenue. It was nascent and now prominent. They could participate in the booster Covid market, and they need to live up to their current market cap of $14 billion. NVAX has to vaccinate a quarter of the world's population to trade at 1x revenues. There's a lot of hope built into the shares that they succeed. He can't buy this and sleep at night.
Pharma & Healthcare
DON'T BUY

It's not worth what it's selling for, and the stock should be lower. Moderna, in contrast, has more drugs in the pipeline, and he prefers this stock.

Pharma & Healthcare
DON'T BUY

NVAX vs. PFE He'd absolutely go with PFE. Investors have been chasing growthy parts of the market and ignoring the stable areas. Vaccines don't move the needle for PFE the way they do for the others, but a great long-term investment if you think rates will stay lower. PFE is mature, decent balance sheet, good valuation.

Pharma & Healthcare
DON'T BUY
There is almost an arms race that is going on with respect to vaccine development. We need to wait to see how human testing is going to work out. There will be lots of volatility in the meantime. He is not interested in playing a specific name -- much like what happened with marijuana stocks. He would look to companies that will provide syringes instead.
Pharma & Healthcare
Showing 1 to 12 of 12 entries
  • «
  • 1
  • »

Novavax Inc(NVAX-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 4

Total Signals / Votes : 5

Stockchase rating for Novavax Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novavax Inc(NVAX-Q) Frequently Asked Questions

What is Novavax Inc stock symbol?

Novavax Inc is a American stock, trading under the symbol NVAX-Q on the NASDAQ (NVAX). It is usually referred to as NASDAQ:NVAX or NVAX-Q

Is Novavax Inc a buy or a sell?

In the last year, 5 stock analysts published opinions about NVAX-Q. 1 analyst recommended to BUY the stock. 4 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novavax Inc.

Is Novavax Inc a good investment or a top pick?

Novavax Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Novavax Inc.

Why is Novavax Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novavax Inc worth watching?

5 stock analysts on Stockchase covered Novavax Inc In the last year. It is a trending stock that is worth watching.

What is Novavax Inc stock price?

On 2022-11-30, Novavax Inc (NVAX-Q) stock closed at a price of $16.515.